Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07060248

A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.

To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Renal Cell Carcinoma (RCC) Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Second Xiangya Hospital

Changsha, Hunan, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma).
  • Contrast-enhanced CT scan was performed preoperatively.

Exclusion criteria

  • Pure cystic clear cell renal cell carcinoma
  • Poor-quality CT images

Treatment and study plan

Primary outcomes

  1. CT-based radiomics analysis for benign and malignant tumor differentiation

    Time frame: within 1 month

    Histopathological diagnosis served as the gold standard, with tumors classified into: (1) Benign renal tumors: Including lipid-poor angiomyolipoma and renal oncocytoma; (2) Malignant renal tumors: Comprising clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma

  2. CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC)

    Time frame: within 1 month

    Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low grade ccRCC: Including WHO/ISUP grade 1-2 ccRCC; (2) high grade ccRCC: Including WHO/ISUP grade 3-4 ccRCC

  3. CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC)

    Time frame: within 1 month

    Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low T-stage RCC: Including T1-2 RCC; (2) high T-stage RCC: including T3-4 RCC

Sponsors and collaborators

Lead sponsor

Second Xiangya Hospital of Central South University

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 11, 2025
Registry last updated
Jul 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.